Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017

Executive Summary

Before election day, the idea of a new transferrable exclusivity incentive seemed like an extreme long shot for enactment. But now advocates think it has a real chance – and a strategy to redraft the idea to answer Democratic critics and avoid a high CBO score.

Advertisement

Related Content

Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Antibiotic Incentives: Pfizer’s Read Touts Exclusivity Voucher
Antibiotic Development: ‘Wildcard Exclusivity’ Proposal Returns
Value-Based Reimbursement For Antibiotics Gets Skeptical Reception
Doubling Down On Antibiotic Incentives: Congress, Obama Administration Drafting Proposals

Topics

Advertisement
UsernamePublicRestriction

Register

PS119542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel